Retinal imaging device manufacturer Optos has announced the launch of Silverstone RGB, which it says is the most advanced product in the company’s history.
A media release said the RGB, built on its flagship Silverstone platform, delivered an unmatched suite of nine imaging modalities in a single device, establishing a new benchmark in retinal imaging.
“Silverstone RGB represents a transformative step forward for eyecare professionals,” said Mr Masayuki Numako, director and executive vice president head of Healthcare Business Division, Nikon Europe B.V.
“By combining 200° single-shot ultra-widefield optomap technology, true-to-life color accuracy, and advanced swept-source OCT, clinicians can evaluate retinal pathology with unparalleled confidence, and efficiency.”
Optos said Silverstone RGB offered the broadest spectrum of retinal imaging capabilities available, enabling clinicians to capture, visualise, and analyse pathology across every layer of the retina.
The nine modalities include optomap colour RGB for true-to-life retinal color imaging, optomap colour RG as the proven clinical standard, supported by more than 3,000 peer-reviewed studies, optomap fluorescein angiography (FA) for vascular evaluation and disease detection, optomap indocyanine green angiography (ICG) for enhanced choroidal and vascular imaging, optomap Sensory Red-Free for highlighting nerve fibre and vascular structures, optomap Choroidal Imaging for deep tissue visualisation, optomap Green Autofluorescence (AF) for identifying RPE changes and metabolic activity, optomap Blue Autofluorescence (AF) for visualising subtle retinal pathology, and Swept-Source OCT for high-resolution, navigable imaging anywhere in the retina
Silverstone RGB debuted at the American Academy of Ophthalmology (AAO) in Orlando, Florida, on 18 October.
For more information, visit www.optos.com
